FDA Clears NRX-101 + TMS Combo for Severe Depression

What the FDA Authorization Means

On June 22, 2026, Stock Titan reported that the FDA has authorized NRx Pharmaceuticals to offer NRX-101 in combination with transcranial magnetic stimulation (TMS) for patients with severe depression. The move marks a notable step for a treatment approach that pairs a pharmacological NMDA-pathway agent with a non-invasive neurostimulation device in the same protocol.

NRX-101 is a fixed-dose oral combination of D-cycloserine and lurasidone. D-cycloserine acts as a partial agonist at the glycine co-agonist site of the NMDA receptor — the same receptor complex targeted by ketamine, though through a distinct binding mechanism and with a very different pharmacological profile. Lurasidone is an atypical antipsychotic with serotonin and dopamine receptor activity, added to support mood stabilization. The combination was originally developed with post-acute severe bipolar depression in mind, particularly as a step-down agent following initial stabilization.

TMS, meanwhile, delivers focused magnetic pulses to cortical regions involved in mood regulation, most commonly the dorsolateral prefrontal cortex. Approved by the FDA for major depressive disorder since 2008, TMS has also been used off-label in bipolar depression contexts. Pairing it with an NMDA-modulating drug like NRX-101 reflects a growing clinical interest in multimodal approaches that target both synaptic plasticity and cortical excitability simultaneously.

Where NRX-101 Fits in the Ketamine Landscape

For anyone already familiar with low-dose ketamine or esketamine (Spravato) treatment, NRX-101's mechanism is worth understanding in context. Ketamine's rapid antidepressant effect is widely attributed to NMDA receptor blockade and the downstream surge in AMPA receptor signaling, which promotes synaptic remodeling. D-cycloserine operates differently — it is a partial agonist rather than a channel blocker, meaning it modulates rather than broadly inhibits NMDA activity. This makes NRX-101 a mechanistic cousin to ketamine, not a direct substitute.

NRx Pharmaceuticals has positioned NRX-101 partly as a maintenance option following acute ketamine or esketamine treatment — a phase of care that remains one of the harder clinical problems in this field. Low-dose ketamine can produce rapid symptom relief, but sustaining that relief requires either repeated infusions or transition to another agent. If NRX-101 demonstrates durable effectiveness as a bridge or continuation strategy, it could complement rather than compete with existing ketamine protocols.

The combination with TMS adds another dimension. Researchers have published preliminary findings suggesting that TMS may potentiate or extend the effects of NMDA-acting agents, though the evidence base is still developing. Whether the FDA's authorization is for a specific clinical trial protocol, an expanded access pathway, or a commercial offering under a particular designation was not detailed in the available reporting, so the precise regulatory mechanism remains to be confirmed from the company's official filings.

What to Watch Going Forward

Several questions will determine how meaningful this development is in practice. First, the exact scope of the FDA's authorization matters: expanded access programs serve a small population under specific criteria, while broader commercial or IND-based approvals open the door to wider clinical use. NRx's official communications and SEC filings will clarify this.

Second, the clinical evidence base for NRX-101 combined with TMS needs scrutiny. D-cycloserine has a mixed history in psychiatry — early trials in anxiety and PTSD produced inconsistent results, and its application in mood disorders is more recent. Lurasidone has an established FDA approval for bipolar depression on its own, lending some confidence to that component. How the two-drug combination performs against TMS alone, or against standard-of-care pharmacotherapy, will require robust trial data to assess.

Third, for the ketamine treatment community specifically, this development reinforces the broader trend toward individualized, sequenced care for treatment-resistant depression. The question of what comes after acute ketamine stabilization — whether that's oral NMDA modulators, TMS, continued low-dose ketamine maintenance, or some combination — is one of the field's most active areas. NRX-101's progress, if borne out by trial data, could eventually give clinicians another evidence-backed tool for that critical maintenance window.

For now, this is a regulatory milestone worth tracking, not a clinical practice change. Readers managing their own low-dose ketamine treatment should consider it background context for how the field is evolving, rather than immediate guidance for their care plan.